3. As of noon trading, Gilead ( GILD) is down $0.54 (-1.1%) to $47.66 on light volume Thus far, 3.5 million shares of Gilead exchanged hands as compared to its average daily volume of 9.8 million shares. The stock has ranged in price between $47.56-$48.37 after having opened the day at $48.25 as compared to the previous trading day's close of $48.20. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $73.1 billion and is part of the drugs industry. The company has a P/E ratio of 29.3, above the S&P 500 P/E ratio of 17.7. Shares are up 31.2% year to date as of the close of trading on Tuesday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, increase in net income, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Gilead Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.